Parabilis Medicines, Inc. Common Stock (PBLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Parabilis Medicines, Inc. Common Stock (PBLS) has a cash flow conversion efficiency ratio of -0.201x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-49.20 Million) by net assets ($244.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Parabilis Medicines, Inc. Common Stock balance sheet quality to measure how much of total assets are equity-financed.
Parabilis Medicines, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Parabilis Medicines, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Parabilis Medicines, Inc. Common Stock debt service capacity to assess how comfortably operating cash covers total debt obligations.
Parabilis Medicines, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Parabilis Medicines, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IGO Ltd
AU:IGO
|
0.014x |
|
Cleanaway Waste Management Ltd
AU:CWY
|
0.060x |
|
Hiwin Technologies Corp
TW:2049
|
0.044x |
|
MANDARIN ORIENTAL DL-05
F:1C4
|
0.007x |
|
Shanghai Xinmei Real Estate Co Ltd Class A
SHG:600732
|
-0.011x |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
0.029x |
|
WPP PLC ADR
F:0WPA
|
-0.065x |
|
Downer Edi Ltd
AU:DOW
|
0.105x |
Annual Cash Flow Conversion Efficiency for Parabilis Medicines, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Parabilis Medicines, Inc. Common Stock from 2024 to 2025. For the full company profile with market capitalisation and key ratios, see PBLS company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-16.52 Million | $-123.71 Million | 7.487x | +507.82% |
| 2024-12-31 | $56.44 Million | $-103.61 Million | -1.836x | -- |
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein … Read more